# Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation

> **NCT07729332** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Phentermine Pill
- **DRUG:** Orforglipron

## Key facts

- **NCT ID:** NCT07729332
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-01
- **Primary completion:** 2031-07-31
- **Final completion:** 2031-07-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07729332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07729332, "Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07729332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*